These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23461428)

  • 1. Adherence to varenicline and associated smoking cessation in a community-based patient setting.
    Liberman JN; Lichtenfeld MJ; Galaznik A; Mastey V; Harnett J; Zou KH; Leader JB; Kirchner HL
    J Manag Care Pharm; 2013 Mar; 19(2):125-31. PubMed ID: 23461428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of out-of-pocket pharmacy costs with adherence to varenicline.
    Suehs BT; Davis C; Galaznik A; Joshi AV; Zou KH; Patel NC
    J Manag Care Spec Pharm; 2014 Jun; 20(6):592-600. PubMed ID: 24856597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.
    Xenakis JG; Kinter ET; Ishak KJ; Ward AJ; Marton JP; Willke RJ; Davies S; Caro JJ
    Pharmacoeconomics; 2011 Jun; 29(6):497-510. PubMed ID: 21452908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
    Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
    Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.
    Ebbert JO; Hughes JR; West RJ; Rennard SI; Russ C; McRae TD; Treadow J; Yu CR; Dutro MP; Park PW
    JAMA; 2015 Feb; 313(7):687-94. PubMed ID: 25688780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study.
    Boudrez H; Gratziou C; Messig M; Metcalfe M
    Curr Med Res Opin; 2011 Apr; 27(4):769-75. PubMed ID: 21294601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline: for smoking cessation.
    Rao J; Shankar PK
    Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
    Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
    Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.
    Rose JE; Behm FM
    Am J Psychiatry; 2014 Nov; 171(11):1199-205. PubMed ID: 24934962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis.
    Huang Y; Lewis S; Britton J
    BMC Public Health; 2014 Oct; 14():1024. PubMed ID: 25273646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender difference and effect of pharmacotherapy: findings from a smoking cessation service.
    Walker NJ; van Woerden HC; Kiparoglou V; Yang Y; Robinson H; Croghan E
    BMC Public Health; 2016 Oct; 16(1):1038. PubMed ID: 27716223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.